TriGlytza® Phase 2 Trial Compares Novel Combination Therapy Against Metformin for Type 2 Diabetes
Background
Type 2 diabetes (T2DM) remains challenging, with current treatments often managing symptoms without addressing underlying pancreatic damage and increasing insulin resistance. Many patients, even on therapies like Metformin or Ozempic, eventually lose responsiveness. This highlights a critical gap: the progressive loss of pancreatic beta-cell function. A novel approach targeting inflammation and biological pathways causing ongoing damage is needed to protect the pancreas and reduce insulin resistance, offering a more sustainable long-term solution.
Study Design
A Phase 2, randomized, double-blind, placebo-controlled, dose-ranging, parallel-group study is assessing the efficacy and safety of TriGlytza® (a combination of Celecoxib, Valsartan, and Metformin) compared to Metformin alone. The trial will enroll obese adult T2DM patients whose condition is inadequately controlled on Metformin. The primary endpoint is the change in HbA1c from baseline to 20 weeks. Secondary outcomes include the percentage of participants achieving an HbA1c target of <7.0% and the number of treatment-related adverse events over 25 weeks.
Why It Matters
If successful, this Phase 2 trial could validate TriGlytza® as a superior long-term treatment for Type 2 diabetes, moving beyond symptomatic relief to address root causes like inflammation and insulin resistance. A more effective, affordable, and safer option could significantly improve patient outcomes, potentially preventing severe complications like heart disease, stroke, and kidney damage. This approach, combining existing drugs, offers a faster path to clinical translation compared to de novo drug discovery, potentially leading to a usable protocol sooner for patients struggling with current therapies.
triglytza
metformin
t2dm
obesity
clinical trial
phase 2